Analyst Weighs Patent Cliff Risks Against Insmed's (INSM) Growth Story [Yahoo! Finance]
Insmed, Inc. (INSM)
Last insmed, inc. earnings: 4/30 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insmed.com
Company Research
Source: Yahoo! Finance
results, with total revenue reaching approximately $606 million, up 67% year over year, driven by continued ARIKAYCE growth and the first full year of BRINSUPRI, both of its leading therapies. This topline growth came in at the top end of the current consensus and was 11% above the consensus average of $545 million. Nestor Rizhniak/Shutterstock.com On a full-year basis, ARIKAYCE generated about $434 million globally, exceeding guidance, while BRINSUPRI contributed roughly $173 million in U.S. sales, supported by solid adoption by medical professionals. Management also outlined a robust 2026 outlook, including an expected EU launch of BRINSUPRI, ARIKAYCE revenue guidance of $450-$470 million, and multiple upcoming late-stage clinical readouts. Just before the results, Morgan Stanley analyst Maxwell Skor reviewed Insmed Inc. (NASDAQ:INSM) and lowered his price target marginally to $157 from $158, keeping his Equal Weight rating intact. The analyst remains cautious on large-cap bio
Show less
Read more
Impact Snapshot
Event Time:
INSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INSM alerts
High impacting Insmed, Inc. news events
Weekly update
A roundup of the hottest topics
INSM
News
- Artisan Mid Cap Fund Q4 2025 Performance Discussion And Portfolio Activity [Seeking Alpha]Seeking Alpha
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSMPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSMGlobeNewswire
- Insmed CEO Will Lewis talks its rare disease drug pipeline [CNBC]CNBC
- Insmed (NASDAQ:INSM) was given a new $205.00 price target on by analysts at Truist Financial Corporation.MarketBeat
INSM
Earnings
- 10/30/25 - Miss
INSM
Sec Filings
- 1/13/26 - Form 4
- 1/13/26 - Form 4
- 1/12/26 - Form 144
- INSM's page on the SEC website